FDA ACTIONS
FDA recently alerted pharmacists and other healthcare professionals to the potential for patient injury due to confusing the unapproved prescription topical wart remover Durasal with FDA-approved eye medicine Durezol. » More |
Editor's Pick
Plans re-evaluate their COPD programs in light of changes
New drugs to treat chronic obstructive pulmonary disease (COPD) have increased treatment options. However, they have also caused health plans to re-evaluate their chronic-condition management strategies. » Click here. |
CONTINUING EDUCATION
Also known as syndrome X or metabolic syndrome, this condition can lead to diabetes, hypertension, and cardiovascular disease. For patients, pharmacists are an ideal source of information and support. Earn up to 2 CPE credits. » Click here to login and take the exams. |
CLINICAL NEWS
Silent embolic cerebral infarctions occur in about 1 in 6 patients after undergoing coronary angiography, and the risk is related to the degree of platelet inhibition with aspirin and clopidogrel, a Korean study shows. » More |
|
The ACP Foundation recently published a 31-page primer, Initiative on Atrial Fibrillation and Stroke Prevention, in the hopes of improving the care of patients with atrial fibrillation within health systems. » More |
|
Welcome to the latest public health emergency: Shortages of anti-infective agents. These shortages can adversely affect clinical care and patient outcomes. » More |
|
Risperidone (Risperdal, Janssen) may be more effective than lithium or divalproex sodium (Depakote, Abbott) for the initial treatment of childhood mania but it could lead to potentially serious metabolic side effects, including weight gain, according to a study published online January 2, in the Archives of General Psychiatry. » More |
|
The use of enoxaparin on hospitalized, acutely ill patients wearing elastic stockings with graduated compression did not reduce the rate of death when compared with the use of graduated compression stockings alone, according to a study published December 29, 2011, in the New England Journal of Medicine. » More |
Survey
1) Immediately remove all aliskiren-based products from formulary and recommend switching patients to alternative anti-hypertensive medications
2) Maintain formulary status of aliskiren-based products, but perform RetroDUR to identify and communicate to providers of ALL patients on an aliskiren product
3) Maintain formulary status of aliskiren-based products, but perform RetroDUR to identify and communicate to providers of only ‘high-risk’ patients on such an aliskiren combo
4) Implement new prior authorization and/or new contingent therapy edits on aliskiren products to minimize new patient starts on such combinations
5) Do nothing for the time-being until more definitive direction is provided from FDA
Respond here and see what your colleagues think too.
Want to see the results of our last survey regarding chronic atrial fibrillation management?
Click here. |
|
Confirm your
e-newsletter subscription click here.
To ensure future delivery of email newsletters from Formulary please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff |
Digital Edition |
|
|
|
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
|
